Up to six years of continuous treatment with Briumvi (ublituximab) led to sustained reductions in relapse rates and a low rate of disability progression in people with relapsing forms of […] The post ECTRIMS 2025: Briumvi keeps MS patients relapse-free for 6 years appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Spinal Tap II
Tweet No this has nothing to do with the legendary rubbish British Metal Mockumentary of the band Lumbar Puncture or something like that. It is not Spinal Tap Eleven as you turn up the volume but are we going to see the re-birth of the lumbar puncture. In some countries you get a spinal tap…
You can’t have half a relapse
Tweet In the animules the severity of disease is graded and so we see this or that cure of the Week being offered from the beasties as we see a mega claim for benefit on essentially a marginal difference in score. I have long said you can’t have half a relapse it is a relapse…
ECTRIMS 2025: Vidofludimus calcium shows promise against MS
Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium continues to show a significant effect on disability worsening in people with progressive forms of multiple sclerosis (MS), even in those without signs […] The post ECTRIMS 2025: Vidofludimus calcium shows promise against MS appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
ECTRIMS 2025: Standard Ocrevus dose holds up in PPMS
Increasing the dose of Ocrevus (ocrelizumab) by two- or threefold, depending on a person’s weight, did not provide additional benefit in slowing disability progression compared with the standard regimen in […] The post ECTRIMS 2025: Standard Ocrevus dose holds up in PPMS appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Why is response to cannabis variable ? It’s in your jeans and pumps…Beat yer to it!
Tweet Many years ago we showed that there was genetic control of entry of cannabinoids into the brains of mice. We linked the trait back to Swiss mice that arrived into the USA in 1926. There were two males and 5 female white mice that arrived at the Rockerfellow Institute in New York. They gave…
ECTRIMS 2025: Long-term benefits seen with Mavenclad use in MS
Most people with relapsing forms of multiple sclerosis (MS) given Mavenclad (cladribine) did not experience confirmed disability progression for at least four years after starting on the approved therapy, according […] The post ECTRIMS 2025: Long-term benefits seen with Mavenclad use in MS appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Life with MS has given me a new complex to worry about
I’m not sure what age people begin to care about the lives of birds, but I think I’ve reached that point. I’m not quite at the stage where I name […] The post Life with MS has given me a new complex to worry about appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
ECTRIMS 2025: Ocrevus as good as Gilenya for treating MS in children
Children and adolescents living with multiple sclerosis (MS) seem to benefit at least as much — and for some outcomes, significantly more — from Ocrevus (ocrelizumab) as from treatment with […] The post ECTRIMS 2025: Ocrevus as good as Gilenya for treating MS in children appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Gone
Tweet This week at ECTRIMS 2025 I understand that Biogen did not have a major presence…Have they dumped MS to focus elsewhere. However they have reported a natalizumab v2.0. It is a another humanised antibody. But why bother I wondered what advantage does it have, natalizumab is given at 300mg i.v. every 4 weeks but…